The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status.
Inflammatory bowel disease
Oxidative stress
Ulcerative colitis
Vitamin D
Journal
Nutrition journal
ISSN: 1475-2891
Titre abrégé: Nutr J
Pays: England
ID NLM: 101152213
Informations de publication
Date de publication:
11 03 2019
11 03 2019
Historique:
received:
18
12
2018
accepted:
04
03
2019
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
24
4
2020
Statut:
epublish
Résumé
The optimum dosage for vitamin D supplementation has not yet been elucidated in patients with Ulcerative colitis (UC). The aim of this study was to investigate the effects of two vitamin D regimens in UC patients with vitamin D deficiency. In this double blind randomized clinical trial, 50 patients with mild to moderate UC, who met inclusion criteria, received either 1000 or 2000 IU/day of vitamin D (as low dose or high dose group, respectively) for 12 weeks. Serum 25-hydroxy vitamin D (25-OHD) level, total antioxidant capacity (TAC), and Total Oxidant Status (TOS), the inflammatory bowel disease questionnaire - 9 (IBDQ-9) score and the Simple Clinical Colitis Activity Index Questionnaire (SCCAI) score were assessed before and after intervention. At the end of study, serum 25-OHD levels significantly increased in the high dose group (P < 0.001) and the increase was significantly more than low dose group (6.7 ± 3.8 ng/mL in the high dose group versus 0.2 ± 0.5 ng/mL in the low dose group) (P < 0.001). Serum TOS concentration decreased significantly (- 0.37 ± 0.26) only in the high dose group (P value = 0.023). There was no statistically significant change in serum TAC between two groups during the study. IBDQ-9 mean score significantly increased in high dose group compared to the low dose group (P value = 0.001) and SCCAI score in both groups reduced (- 2.58 ± 2.16 and - 0.9 ± 0.3 in high dose and low dose respectively), while this reduction was significant only in the high dose group (P value ≥0.001). Our results indicate that 2000 IU daily dose of vitamin D can increase serum 25-OHD concentration, and quality of life, while it reduces disease activity in UC patients with vitamin D deficiency. We recommend assessment of the vitamin D status in all patients with UC because they may benefit from vitamin D therapy.
Sections du résumé
BACKGROUND
The optimum dosage for vitamin D supplementation has not yet been elucidated in patients with Ulcerative colitis (UC). The aim of this study was to investigate the effects of two vitamin D regimens in UC patients with vitamin D deficiency.
METHODS
In this double blind randomized clinical trial, 50 patients with mild to moderate UC, who met inclusion criteria, received either 1000 or 2000 IU/day of vitamin D (as low dose or high dose group, respectively) for 12 weeks. Serum 25-hydroxy vitamin D (25-OHD) level, total antioxidant capacity (TAC), and Total Oxidant Status (TOS), the inflammatory bowel disease questionnaire - 9 (IBDQ-9) score and the Simple Clinical Colitis Activity Index Questionnaire (SCCAI) score were assessed before and after intervention.
RESULTS
At the end of study, serum 25-OHD levels significantly increased in the high dose group (P < 0.001) and the increase was significantly more than low dose group (6.7 ± 3.8 ng/mL in the high dose group versus 0.2 ± 0.5 ng/mL in the low dose group) (P < 0.001). Serum TOS concentration decreased significantly (- 0.37 ± 0.26) only in the high dose group (P value = 0.023). There was no statistically significant change in serum TAC between two groups during the study. IBDQ-9 mean score significantly increased in high dose group compared to the low dose group (P value = 0.001) and SCCAI score in both groups reduced (- 2.58 ± 2.16 and - 0.9 ± 0.3 in high dose and low dose respectively), while this reduction was significant only in the high dose group (P value ≥0.001).
CONCLUSION
Our results indicate that 2000 IU daily dose of vitamin D can increase serum 25-OHD concentration, and quality of life, while it reduces disease activity in UC patients with vitamin D deficiency. We recommend assessment of the vitamin D status in all patients with UC because they may benefit from vitamin D therapy.
Identifiants
pubmed: 30871542
doi: 10.1186/s12937-019-0441-7
pii: 10.1186/s12937-019-0441-7
pmc: PMC6419481
doi:
Substances chimiques
Antioxidants
0
Oxidants
0
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Références
Exp Biol Med (Maywood). 2004 Dec;229(11):1136-42
pubmed: 15564440
Int J Colorectal Dis. 2015 Sep;30(9):1255-60
pubmed: 25982462
Gut. 1998 Jul;43(1):29-32
pubmed: 9771402
Adv Biomed Res. 2018 Mar 27;7:45
pubmed: 29657930
Inflamm Bowel Dis. 2015 Nov;21(11):2708-17
pubmed: 26348447
J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S176-85
pubmed: 12000604
Nutr Cancer. 2016;68(3):404-9
pubmed: 27030369
Nutrients. 2015 Jul 27;7(8):6088-108
pubmed: 26225992
Am J Pathol. 2010 Aug;177(2):686-97
pubmed: 20566739
J Am Coll Nutr. 2016;35(2):163-74
pubmed: 26430776
Am J Gastroenterol. 2004 Mar;99(3):457-61
pubmed: 15056085
Aliment Pharmacol Ther. 2014 Jan;39(2):125-36
pubmed: 24236989
Am J Gastroenterol. 2016 May;111(5):720-2
pubmed: 27151121
Expert Rev Clin Immunol. 2010 Jul;6(4):505-8
pubmed: 20594120
J Pediatr Gastroenterol Nutr. 2016 Feb;62(2):252-8
pubmed: 26196201
Am J Physiol Gastrointest Liver Physiol. 2013 May 15;304(10):G917-28
pubmed: 23518681
World J Gastroenterol. 2016 Jan 21;22(3):933-48
pubmed: 26811638
Mediators Inflamm. 2009;2009:297645
pubmed: 19503799
Br J Nutr. 2017 Jul;118(1):11-16
pubmed: 28758603
Dig Dis Sci. 2015 Oct;60(10):3085-91
pubmed: 26031421
Am J Clin Nutr. 1985 Oct;42(4):644-9
pubmed: 4050723
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16
pubmed: 17962355
Med J Islam Repub Iran. 2015 Aug 24;29:253
pubmed: 26793644
Arch Med Res. 2016 May;47(4):304-9
pubmed: 27664491
Clin Gastroenterol Hepatol. 2017 Feb;15(2):240-246.e1
pubmed: 27266980
Am J Gastroenterol. 2016 May;111(5):712-9
pubmed: 26952579
Clin Gastroenterol Hepatol. 2017 Feb;15(2):247-248
pubmed: 27825894
Neuropharmacology. 2001 May;40(6):761-71
pubmed: 11369030
Inflamm Bowel Dis. 2011 Oct;17(10):2116-21
pubmed: 21910173
JPEN J Parenter Enteral Nutr. 2011 May;35(3):308-16
pubmed: 21527593
J Ethnopharmacol. 2011 Jan 27;133(2):780-7
pubmed: 21070844
J Dig Dis. 2015 Nov;16(11):617-33
pubmed: 26316334
J Cardiovasc Transl Res. 2013 Apr;6(2):221-31
pubmed: 23247634
Ann Nutr Metab. 2009;55(4):325
pubmed: 19844088
Ann N Y Acad Sci. 2011 Jan;1217:77-82
pubmed: 21114675
Arq Gastroenterol. 2015 Dec;52(4):260-5
pubmed: 26840465
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
pubmed: 22001864
Arch Med Res. 2015 May;46(4):280-5
pubmed: 26002728
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Indian J Gastroenterol. 2008 Sep-Oct;27(5):186-9
pubmed: 19112187
J Clin Endocrinol Metab. 2012 Jun;97(6):2134-42
pubmed: 22456619
J Gastrointestin Liver Dis. 2008 Dec;17(4):439-44
pubmed: 19104706
Gastroenterol Hepatol (N Y). 2016 Aug;12(8):513-515
pubmed: 27917088